What is our IT-ACTS cell-based platform?

Our Immune Triad Therapy with Armed CAR T-cell Supercharger  (IT-ACTS) platform is at the forefront of precision medicine, designed to deliver potent agents directly to the core of fibrotic tissues and/or solid tumors. By engineering cells to seek out and carry therapeutic agents into pathogenic tissue, our platform targets the core of resistance mechanisms, ensuring that the treatment reaches where it's needed most.

What Makes Us Unique?

Our proprietary platform uniquely targets critical pathways within both pathogenic cells and their microenvironment. Unlike conventional therapies that focus on one pathway, our approach precisely and selectively disrupts multiple resistance and evasion mechanisms at once, leading to more durable responses and better patient outcomes.

At Powerhouse Therapeutics, our purpose is unequivocal: to develop and deliver transformative therapies that address the most formidable challenges in medicine. We are committed to redefining what’s possible across oncology and chronic diseases by challenging existing paradigms and relentlessly pursuing breakthroughs.

Our work is fueled by a profound sense of urgency—driven by the understanding that every day counts for patients and their families. We strive to push the boundaries of innovation, leveraging cutting-edge science to create therapies that not only extend lives but also improve the quality of life for those battling cancer.

Our team of world-class scientists, clinicians, and executives is at the heart of this mission. From the lab bench to clinical trials, we are dedicated to ensuring that our groundbreaking therapies reach those who need them most. Every step we take is guided by rigourous science and our unwavering focus on making a tangible difference in the lives of patients and their families, who inspire our work every day.